Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 04; 25(5):685-700.
-
Tanji Y, Shimada S, Kato M, Akiyama Y, Hatano M, Tsukihara S, Igarashi Y, Kodera K, Okazaki K, Yasukawa K, Umemura K, Kamachi A, Nara A, Yamane M, Ishikawa Y, Mochizuki E, Mochida Y, Ikegami T, Ban D, Uchida S, Tanaka S. Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. EBioMedicine. 2026 Mar; 125:106137.
-
Liu NM, Sholevar CJ, Karimzadeh M, Uppuluri J, Van Dongen C, Graves CE, Campbell MJ, Zamora AE, Judge SJ, Canter RJ. The Immune Biology of the Adrenal Gland Microenvironment and Its Role in Metastatic Progression. Int J Mol Sci. 2026 Jan 23; 27(3).
-
Cosgrove CM, Zamarin D, Conejo-Garcia JR, Hacker KE, Vargas R, Konstantinopoulos PA, Mahdi HS, Gaillard S, Markovina S, Kohn EC, Adams SF. A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era. J Natl Cancer Inst. 2025 Sep 01; 117(9):1774-1783.
-
Aare M, Lazarte JMS, Muthu M, Rishi AK, Singh M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug Deliv Transl Res. 2026 Feb; 16(2):693-710.
-
Wamba BEN, Mondal T, Freenor V F, Shaheed M, Pang O, Bedinger D, Legembre P, Devel L, Bhatnagar S, Leiserowitz GS, Tushir-Singh J. Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. Nat Commun. 2025 Jul 01; 16(1):5748.
-
Akbari B, Hasan MM, Islam SM. Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances. J Drug Target. 2025 Nov; 33(9):1555-1574.
-
Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
-
Kolawole OP, Pramanik A, Kasani-Akula P, Rai S, Janorkar S, Edorodion Z, Gates K, Kundu S, Ray PC. Multifunctional Nanoplatform for Highly Accurate Profiling of Triple-Negative Breast Cancer-Derived Chemo- and Immunotherapy Resistance Exosomes. ACS Appl Bio Mater. 2025 Jul 21; 8(7):5959-5969.
-
Finati M, Cirulli GO, Chiarelli G, Stephens A, Tinsley S, Morrison C, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Bettocchi C, Carrieri G, Rogers C, Abdollah F. The Role of Cytoreductive Nephrectomy in Contemporary Metastatic Renal Cell Carcinoma: An Other-Cause Mortality Match Population-Based Study. Clin Genitourin Cancer. 2025 Aug; 23(4):102374.